Resolution on the results of the expert council on the topic “Modern approaches to the treatment of esophageal cancer”

рак пищевода, иммунотерапия, камрелизумаб, химиотерапия

1. Globocan https://gco.iarc.who.int/media/globocan/factsheets/cancers/6-oesophagus-fact-sheet.pdf, 2022. (дата обращения 22.08.2024)

2. Malignant tumors in Russia in 2022 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova, I.V. Lisichnikova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2023.275 p (In Russ.)

3. Esophagus and cardia cancer - Russian Association of Oncologists. Available at: https://oncology-association.ru/wp-content/uploads/2021/04/kr_rak-pishhevoda-i-kardii_aor_30.03.2021.pdf (Accessed: 15 October 2024).

4. Fedyanin M.Yu., Tryakin A.A., Rays A.B., et al. Meta-analysis of studies on the effectiveness of adding anti-PD1 antibodies to the first-line chemotherapy in advanced esophageal cancer. Malignant tumours. 2023;13(2):29–55 (In Russ.). https://doi.org/10.18027/2224-5057-2023-13-2-3

5. Gao, T.T., Shan J.H., Yang Y.X., et al. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network meta-analysis. BMC Cancer 2022:992. https://doi.org/10.1186/s12885-022-10086-5

6. Chu C.W., Caval T., Alisson-Silva F., et al. Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors. Life Sci Alliance 2024;7(3):e202302368. https://doi.org/10.26508/lsa.202302368

7. Na Z., Yeo S.P., Bharath S.R., et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res 2017;27(1):147–150. https://doi.org/10.1038/cr.2016.77

8. Huang J., Xu J., Chen Yu., et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2020;21(6):832–842. https://doi.org/10.1016/s1470-2045(20)30110-8

9. Luo H., Lu J., Bai Yu., et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA 2021;326(10):916–925. https://doi.org/10.1001/jama.2021.12836

10. Escort-Neo: PCR data favor addition of pCR Data Favor Addition of Immunotherapy to Neoadjuvant Therapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma 2024. Available at: https://dailynews.ascopubs.org/do/escort-neo-pcr-data-favor-addition-immunotherapy-neoadjuvant-therapy-resectable-locally

11. Qin J., Xue L., Hao A., et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial. Nature Medicine 2024;30:2549–2557. https://doi.org/10.1038/s41591-024-03064-w.